Fmoc-L-Tyr(Propargyl)-OH

Chemischer Name: N-alpha-(9-Fluorenylmethyloxycarbonyl)-O-propargyl-L-tyrosine // Synonyme: Fmoc-Tyr(Propargyl)-OH, Fmoc-Tyr(Propargyl), N-Fmoc-O-2-propyn-1-yl-L-tyrosine, (S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-(prop-2-yn-1-yloxy)phenyl)propanoic acid

Art-Nr.:FAA3830
CAS Nr.:1204595-05-0
Formel:C₂₇H₂₃NO₅
Lagertemperatur:2-8°C
Molare Masse:441,48 g/mol

Ab 225,00 €

Gruppiert Produkte - Artikel
Anzahl	Verpackungsgröße	Preis	SKU	Warenverfügbarkeit
	1 g	225,00 €	FAA3830.0001	<10 Arbeitstage
	5 g	850,00 €	FAA3830.0005	<10 Arbeitstage
	25 g	2.400,00 €	FAA3830.0025	Auf Anfrage
Sicherheitsdatenblätter

Skip to the end of the images gallery

Skip to the beginning of the images gallery

references

Neoglycopeptides through direct functionalization of cysteine; C. Vala, F. Chrétien, E. Balentova, S. Lamandé-Langle and Y. Chapleur; Tetrahedron Letters 2011; 52: 17-20. https://doi.org/10.1016/j.tetlet.2010.10.021

Photoinduced addition of glycosyl thiols to alkynyl peptides: use of free-radical thiol-yne coupling for post-translational double-glycosylation of peptides; M. Lo Conte, S. Pacifico, A. Chambery, A. Marra and A. Dondoni; J Org Chem 2010; 75: 4644-7. https://doi.org/10.1021/jo1008178

Lacosamide isothiocyanate-based agents: novel agents to target and identify lacosamide receptors; K. D. Park, P. Morieux, C. Salome, S. W. Cotten, O. Reamtong, C. Eyers, S. J. Gaskell, J. P. Stables, R. Liu and H. Kohn; Journal of medicinal chemistry 2009; 52: 6897-911. https://doi.org/10.1021/jm9012054

On the function and structure of synthetically modified porins; S. Reitz, M. Cebi, P. Reiss, G. Studnik, U. Linne, U. Koert and L. O. Essen; Angew Chem Int Ed Engl 2009; 48: 4853-7. https://doi.org/10.1002/anie.200900457

Non-enzymatic covalent protein labeling using a reactive tag; H. Nonaka, S. Tsukiji, A. Ojida and I. Hamachi; J Am Chem Soc 2007; 129: 15777-9. https://doi.org/10.1021/ja074176d

Isoxazolyl-serine-based agonists of peroxisome proliferator-activated receptor: design, synthesis, and effects on cardiomyocyte differentiation; Z. L. Wei, P. A. Petukhov, F. Bizik, J. C. Teixeira, M. Mercola, E. A. Volpe, R. I. Glazer, T. M. Willson and A. P. Kozikowski; J Am Chem Soc 2004; 126: 16714-5. https://doi.org/10.1021/ja046386l

The Discovery of Macrocyclic XIAP Antagonists from a DNA-Programmed Chemistry Library, and Their Optimization To Give Lead Compounds with in Vivo Antitumor Activity; B. A. Seigal, W. H. Connors, A. Fraley, R. M. Borzilleri, P. H. Carter, S. L. Emanuel, J. Fragnoli, K. Kim, M. Lei, J. G. Naglich, M. E. Pokross, S. L. Posy, H. Shen, N. Surti, R. Talbott, Y. Zhang, N. K. Terrett; J. Med. Chem. 2015; 58(6): 2855–2861. https://doi.org/10.1021/jm501892g

Effective PHIP Labeling of Bioactive Peptides Boosts the Intensity of the NMR Signal; G. Sauer, D. Nasu, D. Tietze, T. Gutmann, S. Englert, O. Avrutina, H. Kolmar, G. Buntkowsky; Angew. Chem. Int. Ed. 2014, 53(47): 12941-12945. https://doi.org/10.1002/anie.201404668

Ultrafast Single-Scan 2D NMR Spectroscopic Detection of a PHIP-Hyperpolarized Protease Inhibitor; A. S. Kiryutin; G. Sauer, D. Tietze, M. Brodrecht, S. Knecht, A. V. Yurkovskaya, K. L. Ivanov, O. Avrutina, H. Kolmar, G. Buntkowsky; Chem.-Eur. J. 2019; 25(16): 4025-4030. https://doi.org/10.1002/chem.201900079

Conjugation Strategy Strongly Impacts the Conformational Stability of a PEG-Protein Conjugate; P. B. Lawrence, W. M. Billings, M. B. Miller, B. K. Pandey, A. R. Stephens, M. I. Langlois, J. L. Price; ACS Chem. Biol. 2016; 11(7): 1805–1809. https://doi.org/10.1021/acschembio.6b00349

In Vitro Membrane Permeation Studies and in Vivo Antinociception of Glycosylated Dmt1-DALDA Analogues; S. Ballet, C. Betti, A. Novoa, C. Tömböly, C. U. Nielsen, H. C. Helms, A. Lesniak, P. Kleczkowska, N. N. Chung, A. W. Lipkowski, B. Brodin, D. Tourwe, P. W. Schiller; ACS Med. Chem. Lett. 2014, 5(4): 352–357. https://doi.org/10.1021/ml4004765